| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
|
Lancet
|
2008
|
19.58
|
|
2
|
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.
|
Lancet
|
2007
|
15.92
|
|
3
|
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
|
N Engl J Med
|
2015
|
12.74
|
|
4
|
Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.
|
Cancer
|
2010
|
7.25
|
|
5
|
Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.
|
J Clin Oncol
|
2008
|
5.27
|
|
6
|
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
|
Lancet Oncol
|
2013
|
4.91
|
|
7
|
Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.
|
J Clin Oncol
|
2010
|
4.43
|
|
8
|
Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial.
|
Cancer
|
2007
|
2.34
|
|
9
|
Predictors of early death risk in older patients treated with first-line chemotherapy for cancer.
|
J Clin Oncol
|
2012
|
2.26
|
|
10
|
Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie.
|
J Clin Oncol
|
2004
|
2.05
|
|
11
|
Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma.
|
Am J Respir Crit Care Med
|
2010
|
1.66
|
|
12
|
Laparoscopic radical prostatectomy in renal transplant recipients.
|
Urology
|
2009
|
1.52
|
|
13
|
Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial.
|
Eur Urol
|
2012
|
1.50
|
|
14
|
Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma.
|
Eur J Cancer
|
2011
|
1.45
|
|
15
|
Therapeutic management of de novo urological malignancy in renal transplant recipients: the experience of the French Department of Urology and Kidney Transplantation from Bordeaux.
|
Urology
|
2009
|
1.45
|
|
16
|
Midterm local efficacy and survival after radiofrequency ablation of lung tumors with minimum follow-up of 1 year: prospective evaluation.
|
Radiology
|
2006
|
1.45
|
|
17
|
Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy.
|
Brain Behav Immun
|
2004
|
1.43
|
|
18
|
Tyrosine-kinase inhibitors in the treatment of muscle invasive bladder cancer and hormone refractory prostate cancer.
|
Arch Esp Urol
|
2010
|
1.41
|
|
19
|
The epithelial-mesenchymal transition-inducing factor TWIST is an attractive target in advanced and/or metastatic bladder and prostate cancers.
|
Urol Oncol
|
2009
|
1.34
|
|
20
|
AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study.
|
Cancer
|
2012
|
1.17
|
|
21
|
Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941.
|
J Urol
|
2007
|
1.13
|
|
22
|
Functional decline in older patients with cancer receiving first-line chemotherapy.
|
J Clin Oncol
|
2013
|
1.02
|
|
23
|
Molecular targeting in the treatment of either advanced or metastatic bladder cancer or both according to the signalling pathways.
|
Curr Opin Urol
|
2008
|
0.97
|
|
24
|
Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms.
|
Expert Opin Drug Saf
|
2014
|
0.97
|
|
25
|
What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI?
|
Cancer Treat Rev
|
2012
|
0.95
|
|
26
|
Efficacy of re-challenging metastatic renal cell carcinoma with mTOR inhibitors.
|
Acta Oncol
|
2011
|
0.95
|
|
27
|
Experience with sunitinib in the treatment of metastatic renal cell carcinoma.
|
Ther Adv Urol
|
2012
|
0.93
|
|
28
|
Case study of the month. Complete histologic remission after sunitinib neoadjuvant therapy in T3b renal cell carcinoma.
|
Eur Urol
|
2009
|
0.91
|
|
29
|
Axitinib: a review of its safety and efficacy in the treatment of adults with advanced renal cell carcinoma.
|
Clin Med Insights Oncol
|
2013
|
0.90
|
|
30
|
Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib.
|
Acta Oncol
|
2014
|
0.90
|
|
31
|
Therapy management with sunitinib in patients with metastatic renal cell carcinoma: key concepts and the impact of clinical biomarkers.
|
Cancer Treat Rev
|
2012
|
0.89
|
|
32
|
Efficacy of sunitinib in advanced medullary thyroid carcinoma: intermediate results of phase II THYSU.
|
Oncologist
|
2010
|
0.87
|
|
33
|
Lung tumors treated with percutaneous radiofrequency ablation: computed tomography imaging follow-up.
|
Cardiovasc Intervent Radiol
|
2010
|
0.87
|
|
34
|
The experimental renal cell carcinoma model in the chick embryo.
|
Angiogenesis
|
2012
|
0.86
|
|
35
|
Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie.
|
World J Urol
|
2005
|
0.86
|
|
36
|
Randomized study of intravenous versus subcutaneous interleukin-2, and IFNalpha in patients with good prognosis metastatic renal cancer.
|
Clin Cancer Res
|
2008
|
0.85
|
|
37
|
Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 Trial.
|
Clin Genitourin Cancer
|
2013
|
0.85
|
|
38
|
A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial.
|
Eur J Cancer
|
2011
|
0.85
|
|
39
|
How to manage intravenous vinflunine in cancer patients with renal impairment: results of a pharmacokinetic and tolerability phase I study.
|
Br J Clin Pharmacol
|
2014
|
0.85
|
|
40
|
The role of surgery for metastatic renal cell carcinoma in the era of targeted therapies.
|
World J Urol
|
2013
|
0.84
|
|
41
|
Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-α2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial.
|
BJU Int
|
2010
|
0.84
|
|
42
|
Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice.
|
Cancer Invest
|
2010
|
0.84
|
|
43
|
Emerging antiangiogenics for renal cancer.
|
Expert Opin Emerg Drugs
|
2013
|
0.81
|
|
44
|
Amplification of epidermal growth factor receptor gene in renal cell carcinoma.
|
Eur J Cancer
|
2010
|
0.81
|
|
45
|
Bladder cancer in patients after organ transplantation.
|
Curr Opin Urol
|
2010
|
0.81
|
|
46
|
Targeted therapies in non-muscle-invasive bladder cancer according to the signaling pathways.
|
Urol Oncol
|
2009
|
0.80
|
|
47
|
Gemcitabine or gemcitabine plus oxaliplatin in the first-line treatment of patients with advanced transitional cell carcinoma of the urothelium unfit for cisplatin-based chemotherapy: a randomized phase 2 study of the French Genitourinary Tumor Group (GETUG V01).
|
Eur Urol
|
2011
|
0.80
|
|
48
|
Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications.
|
Cancer Treat Rev
|
2013
|
0.79
|
|
49
|
Targeted therapies in metastatic renal cell carcinoma: overview of the past year.
|
Curr Urol Rep
|
2012
|
0.78
|
|
50
|
[Anti-angiogenic treatment in the management of metastatic renal cell carcinoma].
|
Bull Cancer
|
2008
|
0.78
|
|
51
|
Survival outcomes of bevacizumab in first-line metastatic colorectal cancer in a real-life setting: results of the ETNA cohort.
|
Target Oncol
|
2013
|
0.78
|
|
52
|
Multidisciplinary management of metastatic renal cell carcinoma in the era of targeted therapies.
|
Cancer Treat Rev
|
2012
|
0.78
|
|
53
|
Lapatinib and renal cell carcinoma.
|
Expert Opin Investig Drugs
|
2012
|
0.78
|
|
54
|
Protein kinase inhibitors in renal cell carcinoma.
|
Expert Opin Pharmacother
|
2013
|
0.78
|
|
55
|
Metronomic chemotherapy for renal cancer in the landscape of targeted therapy.
|
Lancet Oncol
|
2010
|
0.78
|
|
56
|
Cutaneous cryptococcosis with alemtuzumab in a patient treated for chronic lymphocytic leukaemia.
|
Br J Haematol
|
2007
|
0.77
|
|
57
|
Clinical benefits of non-taxane chemotherapies in unselected patients with symptomatic metastatic castration-resistant prostate cancer after docetaxel: the GETUG-P02 study.
|
BJU Int
|
2015
|
0.76
|
|
58
|
Combined radiofrequency ablation and antiangiogenic drug for the treatment of recurrent renal tumor.
|
Urology
|
2008
|
0.76
|
|
59
|
Prolonged efficacy of mTOR inhibitors in papillary renal cell carcinoma: progression-free survival lasting for over 3 years, a case report and review of the literature.
|
Target Oncol
|
2013
|
0.76
|
|
60
|
Editorial comment to therapy management of cardiovascular adverse events in the context of targeted therapy for metastatic renal cell carcinoma.
|
Int J Urol
|
2012
|
0.76
|
|
61
|
Optimal management of renal cell carcinoma in the elderly: a review.
|
Clin Interv Aging
|
2013
|
0.75
|
|
62
|
[The mechanism of tumor angiogenesis].
|
Prog Urol
|
2007
|
0.75
|
|
63
|
[Renal involvement in cancer and renal paraneoplastic syndromes].
|
Bull Cancer
|
2012
|
0.75
|
|
64
|
Relationship between Pulmonary Adverse Events and Everolimus Exposure in Japanese and Non-Japanese Patients: A Meta-Analysis of Oncology Trials.
|
Oncology
|
2017
|
0.75
|
|
65
|
Symptomatic neurological epidural metastasis with interleukin-2 therapy in metastatic renal cell carcinoma.
|
Tumori
|
2002
|
0.75
|
|
66
|
[New entities in pathological classification and new therapeutic options in renal cell carcinoma].
|
Bull Cancer
|
2006
|
0.75
|
|
67
|
[Strategy in advanced castration-resistant prostate cancer].
|
Bull Cancer
|
2012
|
0.75
|
|
68
|
[Bladder cancer. Editorial].
|
Bull Cancer
|
2010
|
0.75
|
|
69
|
[Refining the French system of cost assessment for oncology patients following chemotherapy].
|
Bull Cancer
|
2003
|
0.75
|
|
70
|
[Cancer of the prostate: recent findings and the immediate future].
|
Bull Cancer
|
2007
|
0.75
|
|
71
|
Systemic therapy of renal cell carcinoma.
|
World J Urol
|
2014
|
0.75
|